Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference
June 17 2014 - 12:30PM
PR Newswire (Canada)
MISSISSAUGA, ON, June 17, 2014 /CNW/ - Nuvo Research Inc.
(TSX: NRI) a specialty pharmaceutical company with a diverse
portfolio of topical and immunology products today announced that
John London, the Company's President
and Co-Chief Executive Officer will be providing a corporate update
at the Bloom Burton & Co Healthcare Conference on Wednesday, June 18, 2014 in Toronto.
A copy of the presentation will be available on the Company's
website at www.nuvoresearch.com.
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a
specialty pharmaceutical company with a diverse portfolio of
products and technologies. The Company operates two distinct
business units: the Topical Products and Technology (TPT) Group and
the Immunology Group. The TPT Group has four U.S. Food and
Drug Administration (FDA) approved commercial products, a pipeline
of topical and transdermal products focusing on pain and
dermatology and four drug delivery platforms that support the
creation of patented formulations that can deliver actives into or
through the skin. The Immunology Group has two commercial
products, a development program for the treatment of allergic
rhinitis and an immune system modulation platform that has the
potential to support treatments for a broad range of immune system
related disorders. For additional company information
visit www.nuvoresearch.com.
SOURCE Nuvo Research Inc.
Copyright 2014 Canada NewsWire